NCT04794972View on ClinicalTrials.gov

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Recurrent GliomaSolid Tumor
Interventions
DRUG

GNC-039

Administration by intravenous infusion.

Trial Locations (6)

100070

RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

Unknown

RECRUITING

Affiliated Cancer Hospital of Chongqing Medical University, Chongqing

RECRUITING

ZhuJiang Hospital of Southern Medical University, Guangzhou

RECRUITING

Shenzhen Second People's Hospital, Shenzhen

RECRUITING

The First Affiliated Hospital of Xi'an Jiao Tong University, Xian

RECRUITING

West China Hospital，Sichuan University, Chengdu

All Listed Sponsors
collaborator

SystImmune Inc.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT04794972 - A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter